18F-FDG PET SUV repeatability: Lodge reviews available data on repeatability metrics, relative units, log transformation, and asymmetric limits of repeatability in 18F-FDG SUV assessment.
Page 523
Metabolic imaging of glutamine: Zhu and colleagues provide an overview of the potential utility of 11C- and 18F-labeled glutamine tracers for targeting in vivo metabolism of glutamine in cancer cells.
Page 533
Imaging human immune checkpoints: Mayer and colleagues optimize noninvasive immuno-PET imaging of human programmed death-ligand 1 expression in a preclinical mode, using a small high-affinity engineered protein scaffold.
Page 538
Bimodal molecular imaging: Lee and colleagues test the ability of a laparoscopic camera system to detect fluorescent signal emanating from sentinel lymph nodes 2 d after injection of fluorescent-tagged tilmanocept radiolabeled with both 68Ga and 99mTc.
Page 547
18F-FHNP for ERβ expression: Antunes and colleagues report on synthesis and in vitro and in vivo evaluations of a potential estrogen receptor isoform β–selective PET tracer.
Page 554
18F-FES PET in breast cancer: Fowler and Linden offer background and perspective on an article in this issue of JNM on 18F-FES PET/CT prediction of pathologic response to neoadjuvant therapy in patients with estrogen receptor–positive primary breast tumors.
Page 560
18F-FES PET in ER-rich breast cancer: Chae and colleagues investigate the ability of 18F-fluoroestradiol PET/CT imaging to predict pathologic response to neoadjuvant therapy in postmenopausal women with estrogen receptor–rich breast cancer.
Page 563
Radiomics and somatic mutations: Yip and colleagues assess associations (including predictive utility) between 18F-FDG PET–based radiomic features and somatic mutations in patients with non–small cell lung cancer.
Page 569
PET/CT, timing, and pediatric HL: Bakhshi and colleagues report on the significance of interim and end-of-treatment 18F-FDG PET/CT in children with Hodgkin lymphoma, including comparisons with conventional contrast-enhanced CT and Deauville 5-point response assessment.
Page 577
18F-FET PET in brain mets: Unterrainer and colleagues detail 18F-FET uptake characteristics on PET imaging in patients with newly diagnosed and untreated brain metastases and describe potential utility in treatment response assessment.
Page 584
Evans blue–based theranostics: Chen and colleagues detail development of an “add-on” molecule containing a truncated Evans blue dye molecule for prolonged half-life, a metal chelate for radiolabeling in imaging and radiotherapy, and maleimide for conjugation to drug molecules.
Page 590
α-RIT cure of xenografts: Bäck and colleagues explore the influence of targeted 211At-radioimmunotherapy on macrotumor treatment, long-term toxicity, and survival in an ovarian cancer mouse model.
Page 598
PET/CT MPI and radiation damage: Song and colleagues determine the potential value of 13N-ammonia PET/CT myocardial perfusion imaging for early detection of perfusion changes induced by radiation damage.
Page 605
Quantitative small-animal PET: Huang and colleagues demonstrate in a physiologically stable rat model the feasibility of quantitative small-animal 18F-FDG PET by repeated imaging to monitor the time course of variations in the cerebral metabolic rate of glucose utilization.
Page 611
Small-animal PET and HD: Häggkvist and colleagues use a recently reported mouse model in small-animal PET imaging with a range of radioligands to characterize the progression of molecular targets associated with Huntington disease.
Page 617
Tau quantification with 18F-AV1451: Hahn and colleagues outline different strategies for quantification of 18F-AV1451 tau binding, including models with blood sampling and noninvasive alternatives, with potential for applications in neurodegenerative disease.
Page 623
18F-FDG PET in PCA and DLB: Whitwell and colleagues determine whether patterns of hypometabolism or the cingulate island sign differ in patients with clinically diagnosed posterior cortical atrophy or probable dementia with Lewy bodies.
Page 632
Prediction of Aβ accumulation: Guo and colleagues investigate whether regional patterns of longitudinal β-amyloid accumulation can be predicted by baseline amyloid 18F-florbetapir PET imaging in patients with incipient and manifest dementia associated with Alzheimer disease.
Page 639
Hybrid detection modalities: KleinJan and colleagues describe clinical applications of 2 configurations, each of which combines γ-detection and an open surgery fluorescence camera, in guiding sentinel node biopsy with an indocyanine green–99mTc-nanocolloid.
Page 646
Clustering of dynamic PET tumor images: Katiyar and colleagues devise and validate an unsupervised segmentation algorithm for assessment of tumor heterogeneity using dynamic 18F-FDG PET.
Page 651
90Y PET/CT image reconstruction with BPL: Rowley and colleagues evaluate new reconstruction software using a Bayesian penalized likelihood reconstruction algorithm in phantom and patient PET scans after selective internal radiotherapy.
Page 658
99mTc-duramycin SPECT and therapy response: Elvas and colleagues compare the predictive power of cell death imaging using 99mTc-duramycin SPECT with the current gold standard 18F-FDG PET for treatment response evaluation after targeted therapy.
Page 665
PET imaging of αvβ6 integrin: Notni and colleagues describe preclinical PET imaging of the cellular transmembrane receptor αvβ6 integrin using 68Ga-labeled nonapeptides, with a wide range of potential clinical utilities.
Page 671
ABCB1 function at blood–retina barrier: Bauer and colleagues assess P-glycoprotein transport activity at the human blood–retina barrier using (R)-11C-verapamil PET.
Page 678
- © 2017 by the Society of Nuclear Medicine and Molecular Imaging.
Jump to section
Related Articles
Cited By...
- No citing articles found.